Slide 1: Exchange filing cover letter
June 6, 2019 Corporate Relationship Department Manager – Listing M/s. BSE Ltd M/s. National Stock Exchange of India Ltd Dalal Street, Fort “Exchange Plaza”, Bandra – Kurla Complex Mumbai 400 001 Bandra (E) Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir, Please find enclosed herewi
Slide 2: Investor Presentation Q4 FY19
INVESTOR PRESENTATION Q4 FY19, May 2019
Slide 3: Disclaimer / Important Disclosure
Disclaimer / Important Disclosure THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background
Slide 4: Natco Pharma at a Glance
Represents Natco consolidated Pharmarevenue at a fromGlance operations (gross) Market capitalization as of 31 March 2018, using INR / USD exchange rate of 65.04 As of March 31, 2018 integrated pharmaceutical company with presence across geographies - India, US and Rest of World (ROW) Vertically Re
Slide 5: Track Record of Consistent Growth
Track Record of Consistent Growth Revenue Ownership Structure(3) INR mn 20,789 22,424 22,247 Promoters, Public, 10,897 49.01% 50.99% FY2016 FY2017 FY2018 FY2019 EBIDTA & EBIDTA Margins 25.9% 33.5% 43.2% 41.6% INR mn 9,688 9,250 Natco Pharma’s Stock Performance over the years(4) 6,973 2,823 FY2016 FY
Slide 6: Key Business Segments - Pharma
Key Business Segments- Pharma Formulations API Subsidiaries Domestic International Exports (Domestic & Exports) Strong brand position in the Focused on complex generics for Strategically important division Operations in Brazil, Canada, domestic oncology and Hepatitis- the US Singapore, Austr
Slide 7: US Market - Focus on Complex Generics
US Market - Focus on Complex Generics & be Nimble US FDF product portfolio is predominantly focused on high-barrier-to-entry products that are typically characterised by one or more of the following: - Intricate chemistry - Challenging delivery mechanism - Difficult or complex manufacturing process
Slide 8: Strong Growth in Domestic Formulations Business
Brand Molecule Dosage Form Therapautic Segment Strong Growth in Domestic Formulations Business Domestic Formulation Sales(1): Market Leading Growth Domestic Formulations overview, FY2019 Launched 6 products during the year. Target 6-8 products every year. Positioned #1 in sales of branded oncolo
Slide 9: Strong Market Position in Domestic Oncology Segment
Strong Market Position in Domestic Oncology Segment Oncology Division Overview Oncology Revenue – Gross (INRmn) Over 15 years of strong presence in oncology segment. Positioned #1 in sales of branded oncology medicines in India. INR mn Portfolio of well recognized brands – 6 brands with INR 100m
Slide 10: Expanding RoW Presence
Expanding RoW Presence Focus on Canada, Brazil and other RoW markets Europe Canada Distribution arrangements with our business partner to sell our products in Expanded beyond Oseltamivir with Eastern Europe, UK and Germany key filings in oncology segment 16 approvals in place Filed Liposomal
Slide 11: In-House API Development with Vertical Integration
In-House API Development with Vertical Integration for Key Formulation Products Mekaguda Facility Chennai Facility Strategically important business – develops APIs primarily for captive consumption of its FDF portfolio as well as third party sales Portfolio of 45 US DMFs(1) with with niche produ
Slide 12: Research & Development Capabilities
Research & Development Capabilities R&D capabilities demonstrated by its complex and niche product filings in formulations and API segments Two research facilities with capabilities across synthetic chemistry, biotech & fermentation, nano 36 ANDAs Approved(2) pharmaceuticals, new drug discovery &
Slide 13: Commitment to Manufacturing Excellence
Commitment to Manufacturing Excellence with a Culture of Quality and Compliance International Markets Formulations Kothur Facility Visakhapatnam Facility Capability Tablets, Capsules, Pellets, Injectables Cytotoxic & other Oral Solid Dosages Key Operationally ready Regulatory GMP, USFDA, Ger
Slide 14: Experienced Management
Experienced Management Mr. V.C Nannapaneni Holds Masters degree in Pharmaceutical Administration from the Long Island University,USA Chairman and Managing Director Over 4 decades of experience in the pharmaceutical industry Mr. Rajeev Nannapaneni Holds bachelors degree in Quantitative Economic
Slide 15: Natco's Near and Long-Term Goals
Natco’s Near and Long-Term Goals Domestic Branded Formulations Complex Generics & Export Markets Maintain leadership position in Oncology and Focus on growth in key subsidiaries of Canada & Gastro-Hepatology segment Brazil Near-term Strategies Intensify focus on CnD pipeline for niche Intens
Slide 16: Historical Record of Topline and Earnings Growth
Historical Record of Topline and Earnings Growth Total Gross Revenue(1) (INRmn) EBITDA (INRmn) and EBITDA Margin (%) 25.9% 33.5% 43.2% 41.6% INR mn INR mn 22,424 22,247 9,688 9,250 20,789 6,973 10,897 2,823 FY2016 FY2017 FY2018 FY2019 FY2016 FY2017 FY2018 FY2019 PAT(2) (INRmn) and PAT Margin (%) ROC
Slide 17: Consolidated Financials
Consolidated Financials Consolidated Profit & Loss Statement (INRmn) Consolidated Balance Sheet (INRmn) Particulars 31-March-2019 31-March-2018 Particulars 31-March-2019 31-March-2018 Revenue ASSETS Revenue from operations 20,945 22,020 Non-current assets (a) Property, plant and equipment 12,185 10,
Slide 18: Quarterly Financial Summary
Quarterly Financial Summary Segmental Breakdown (INR Mn) Consolidated Financial Results (INRMn) Revenue Divisionc Q4FY19 FY19 Q4FY18 FY18 Q4FY19 FY19 Q4 FY18 FY18 API Gross Revenue 697 3,030 597 2,854 Total Revenues 4,867 22,247 7,879 22,424 Formulation export 1,430 8,847 4,922 10,419 and profit sha